Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03678025 · ClinicalTrials.gov registry record · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
A Phase 3 study of Stage IVB Prostate Cancer AJCC v8 and Stage IV Prostate Cancer AJCC v8, sponsored by SWOG Cancer Research Network.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,273
- Enrollment target
- 20
- Study locations
NCT03678025 is a Phase 3 study of Stage IVB Prostate Cancer AJCC v8 and Stage IV Prostate Cancer AJCC v8 that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 1,273 participants, above the 149-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (754% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT03678025, a Phase 3 study of Stage IVB Prostate Cancer AJCC v8 and Stage IV Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by SWOG Cancer Research Network.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,273 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Abiraterone
- DRUG Bicalutamide
- DRUG Degarelix
- DRUG Flutamide
Study Locations (20)
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Community Cancer Institute - Clovis
- University Oncology Associates - Clovis
- City of Hope Comprehensive Cancer Center - Duarte
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fremont - Fremont
- Fresno Cancer Center - Fresno
- Kaiser Permanente-Fresno - Fresno
- UC San Diego Moores Cancer Center - La Jolla
- Tibor Rubin VA Medical Center - Long Beach
- Los Angeles County-USC Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Fremont - Rideout Cancer Center - Marysville
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Cancer Center at Saint Joseph's - Phoenix
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,273 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2031-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03678025
The ClinicalTrials.gov registry entry for NCT03678025 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,273 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 149-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (754% higher). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Stage IVB Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT03678025 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03678025 about?
NCT03678025 is a clinical study titled "Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer". This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation ther...
What is the current status of trial NCT03678025?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,273 participants. The study started on 2018-09-24. Estimated completion is 2031-10-01.
What conditions does trial NCT03678025 study?
This clinical trial studies the following conditions: Stage IVB Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma.
What interventions are being tested in trial NCT03678025?
The interventions under investigation include: Docetaxel (DRUG), Abiraterone (DRUG), Bicalutamide (DRUG), Degarelix (DRUG), Flutamide (DRUG).
Who is sponsoring clinical trial NCT03678025?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03678025 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IVB Prostate Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
RECRUITING · Phase 3
-
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RECRUITING · Phase 3
-
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
RECRUITING · Phase 3
-
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
RECRUITING
-
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Stage IVB Prostate Cancer AJCC v8
All registered trials for this condition
Stage IV Prostate Cancer AJCC v8
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.